ASPET

AUGUST 10, 2023

In cell-based assays, pegozafermin had a similar receptor engagement profile as native FGF21, with approximately 8-fold higher potency at FGF receptor 1 (FGFR1). These findings provide evidence that pegozafermin is a promising candidate molecule for the treatment of patients with NASH or SHTG.

Cell Based Assays 100

Cell Based Assays Pharmacokinetics Regulations Treatment 100

Broad Institute

JUNE 30, 2023

Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize. Fat cells stained yellow to show the actin cytoskeleton, plasma membrane, and Golgi apparatus. “I

Small Molecule 105

Small Molecule Cell Based Assays Disease Assay Development 105

Broad Institute

JUNE 21, 2023

Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize.

Small Molecule 52

Small Molecule Cell Based Assays Medical Schools Disease 52

BMG Labtech

MARCH 8, 2023

In biology , scientific research on cell metabolism focuses on different topics such as understanding the fundamental metabolic processes, metabolic changes and their role in diseases (including cancer cell and tumor metabolism), the development of therapies, the identification of unknown metabolic processes and metabolites, etc.

Molecular Biology 52

Molecular Biology Production Cell Based Assays Disease 52

Agency IQ

APRIL 12, 2024

BY RACHEL COE, MSC | APR 11, 2024 1:06 PM CDT Regulatory background: Product potency and assays As defined in statute , the FDA uses the term “potency” to refer to the “specific ability or capability” of a product to “effect a given result.” morphological cell changes or alterations in protein production or expression).

Production 40

Production FDA Therapies Biochemical Assays 40